LATEST ARTICLES

8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in...

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for...

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger...

Jul. 1, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger...

Distinct clinical profiles of Huntington’s disease can be associated with two specific neural signatures

Cognitive-motor and psychiatric profiles of Huntington's disease show a different pattern of brain alterations The identification of specific neural signatures can help develop specific biomarkers...

BGU Scientists Duplicate Blood-Brain Barrier Outside the Body

​Scientists can't make a living copy of your brain outside your body. That's the stuff of science fiction. But in a new study, they...